BankPlus Trust Department Takes Position in Boston Scientific Co. (NYSE:BSX)

BankPlus Trust Department purchased a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,238 shares of the medical equipment provider’s stock, valued at approximately $736,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Boston Scientific by 4.4% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after buying an additional 173,034 shares during the last quarter. Mechanics Bank Trust Department purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $415,000. Highland Capital Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth approximately $4,887,000. Covenant Asset Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth approximately $3,405,000. Finally, Brookstone Capital Management lifted its holdings in shares of Boston Scientific by 23.7% during the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider’s stock worth $9,455,000 after purchasing an additional 20,307 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 6th. Morgan Stanley raised their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Thursday. Citigroup lifted their price target on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Barclays increased their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $107.39.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 139,630 shares of company stock worth $14,467,616. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $104.44 on Monday. The stock has a market capitalization of $154.12 billion, a P/E ratio of 83.55, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $65.52 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm’s 50-day moving average is $97.98 and its two-hundred day moving average is $89.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.